{"id":98817,"date":"2026-06-22T05:00:47","date_gmt":"2026-06-22T03:00:47","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?p=98817"},"modified":"2026-06-22T21:01:48","modified_gmt":"2026-06-22T19:01:48","slug":"a-new-wave-of-clinical-data-innovation-faster-timelines-and-better-experiences","status":"publish","type":"post","link":"https:\/\/pantheon.veeva.com\/eu\/blog\/a-new-wave-of-clinical-data-innovation-faster-timelines-and-better-experiences\/","title":{"rendered":"A New Wave of Clinical Data Innovation: Faster Timelines and Better Experiences"},"content":{"rendered":"

Each year<\/a> at Veeva R&D and Quality Summit, biopharma, sites, and CROs showcase how their organizations innovate and achieve efficiency amidst growing clinical trial complexity. This year, the momentum centered on a unified mission: breaking down silos to build a truly connected clinical ecosystem that elevates the trial experience for sponsors, CROs, sites, and, most importantly, patients. <\/p>\n

We shared key innovations that will finally bridge the current gap between these stakeholders and address the lack of a global standard to connect and map clinical data. For example, with Veeva eSource<\/a>, sites are in control of the technology and whether they choose to adopt it as their standard. This will help eSource adoption to scale where previous sponsor-owned (and imposed) tools have not.\n<\/p>\n

Risk-based quality management (RBQM)<\/a> is a capability that has been around for many years, but still with relatively low industry adoption. Veeva RBQM will be delivered within Veeva CTMS and Veeva CDB without adding another system to the clinical technology landscape.<\/p>\n

A top 20 biopharma director of data management said that, \u201cHaving Veeva CDB as a center for data orchestration and high level management of risk \u2013 interlinking with different functions \u2013 gives a connected landscape that will provide oversight of the data. That value-driven cleaning in a risk-based approach will be key for assessing quality and driving change.\u201d <\/p>\n

By focusing on innovating for value, we will deliver three AI agents<\/strong> this year to automate processes across study build, testing, data collection, and data cleaning. These AI agent-based automations will help reduce burden for sites and data managers.\n<\/p>\n

\n
\n

“I\u2019m excited about Veeva\u2019s AI vision; that you\u2019re leaning into new technology and doing it in a use case-based way.”<\/p>\n

\n
Product Director<\/h6>\n

Top 20 biopharma<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n

These much anticipated innovations will add to the value now being achieved by the industry using the Veeva Clinical Platform:<\/p>\n

Modernizing eCOA operations and site experiences<\/h2>\n

Fortrea<\/strong>: By changing ways of working, Fortrea is accelerating eCOA timelines and improving the user experience.<\/p>\n

Across their portfolio of Veeva eCOA studies, Fortrea is delivering consistently with high patient compliance and de-risking the studies. Key results include:<\/p>\n